br The study is a
The study is a register-based observational study and has some limitations. Unmeasured confounding can be present. However, the patients were matched by propensity score based on for example co-morbidity, BMI, year of surgery and thereby diﬀerences in treatments strategies are taken into account. Furthermore, only information re-garding redeemed prescriptions and not actual intake was available.
As tumor regression following chemo-radiotherapy is significantly associated with all-cause mortality, DFS and local recurrence  an increasing interest in the understanding of treatment adjuncts to en-hance tumor response to therapy is developing, and drug repurposing Surgical Oncology 28 (2019) 62–66
Disease-free survival, Recurrence-free survival and All-cause mortality.
Patients with diabetes were matched with non-diabetics 1:2 by propensity score. The propensity score was estimated by age at diagnosis, sex, Charlson comorbidity index, BMI, smoking, alcohol consumption, LY 379268 node status, and year of surgery. The patients are in the subgroup analysis classified in met-formin monotherapy, other antidiabetic medication in monotherapy or in treatment with a combination of diﬀerent antidiabetic medication. *the fre-quency and percentage of the event.
for anti-cancer treatments is gaining momentum. A recent review re-ported promising results for statins and aspirin in increasing the re-sponse to chemo-radiotherapy in patients with rectal cancer . However, any new drugs given to patients already burdened by a di-agnosis of cancer, radiotherapy treatment and the side eﬀects of long course chemotherapy need to have proven eﬃcacy. Randomized con-trolled trials investigating the drugs singularly or in combination to determine whether they confer an increase in response to chemo-radiotherapy are needed.
In conclusion, our study does not support that diabetes or met-formin use are associated with response to neoadjuvant chemo-radio-therapy in terms of DFS, RFS or all-cause mortality.
Conflicts of interest and source of funding
The work was supported by an unrestricted grant from the Region of Zealand and the Region of Southern Denmark Joint Research Foundation. The foundation had no influence on the design or conduct of the study, collection, management, analysis or interpretation of the data or preparation, review or approval of the manuscript.
Appendix A. Supplementary data
T. Fransgaard et al.
neoadjuvant chemoradiotherapy in the management of rectal cancer, Ann. Surg.
Contents lists available at ScienceDirect
Advances in Medical Sciences
journal homepage: www.elsevier.com/locate/advms
Original research article
Association between gastric myoelectric activity disturbances and dyspeptic T symptoms in gastrointestinal cancer patients
Aneta L. Zygulskaa, , Agata Furgalab, Krzysztof Krzemienieckia,c,1, Beata Wlodarczykb, Piotr Thorb a Department of Oncology, University Hospital in Cracow, Cracow, Poland b Department of Pathophysiology, Jagiellonian University Medical College, Cracow, Poland c Department of Oncology, Jagiellonian University Medical College, Cracow, Poland
Gastric myoelectric activity
Purpose: Dyspeptic symptoms present a severe problem in gastrointestinal (GI) cancer patients. The aim of the study was to analyze an association between gastric myoelectric activity changes and dyspeptic symptoms in gastrointestinal cancer patients. Material and Methods: The study included 80 patients (37 men and 43 women, mean age 61.2 ± 7.8 years) diagnosed with GI tract malignancies: colon (group A), rectal (group B) and gastric cancers (group C). Gastric myoelectric activity in a preprandial and postprandial state was determined by means of a 4-channel electro-gastrography. Autonomic nervous system was studied based on heart rate variability analysis. The results were compared with the data from healthy asymptomatic controls.
Results: In a fasted state, GI cancer patients presented with lesser percentages of normogastria time (A:44.23 vs. B:46.5 vs. C:47.10 vs. Control:78.2%) and average percentage slow wave coupling (ACSWC) (A:47.1 vs. B:50.8 vs. C:47.2 vs. Control:74.9%), and with higher values of dominant power (A:12.8 vs. B:11.7 vs. C:12.3 vs. Control:10.9) than the controls. Patients did not show an improvement in the percentage of normogastria time, dominant power, dominant frequency and ACSWC in response to food. The severity of dyspeptic symptoms correlated with the values of electrogastrography parameters. Patients showed lower values of heart rate variability parameters than the healthy controls, that indicate abnormal autonomic nervous system activity.